Program
human acellular vessel extra-cellular matrix
Also written as “Acellular Tissue Engineered Vessel (ATEV)”, “Acellular Tissue Engineered Vessel” and “Acellular Tissue Engineered Vessel (Symvess)”.
Its studies are mostly in Vascular System Injuries · Wounds and Injuries · Kidney Failure, Chronic, led by Humacyte.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Humacyte | 43 open or running | phase 4since Aug 7, 2026 | Dec 21, 2016 | Jun 2027phase 3 · NCT05908084 |
Also a collaborator on its studies: IQVIA Biotech.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2016First study: phase 3 study in Wounds and InjuriesFirst studyNCT03005418 · 72 enrolled · United States, Israel
- Apr 28, 2023Phase 3 study in Kidney Failure, ChronicNCT05908084 · 121 enrolled · United States
- Aug 3, 2026Phase 3 study in Wounds and InjuriesNCT07762313 · 10 planned
- Aug 7, 2026Phase 4 study in Vascular System InjuriesNCT07762794 · 125 planned
Ahead
- Jun 2027Primary completion: phase 3 study in Kidney Failure, ChronicNCT05908084
- Dec 2028Primary completion: phase 3 study in Wounds and InjuriesNCT07762313
- Sep 2030Primary completion: phase 4 study in Vascular System InjuriesNCT07762794
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07762794Vascular System Injuries | 4 | Not yet recruiting | Sep 2030 | 125 |
| NCT07762313Wounds and Injuries | 3 | Not yet recruiting | Dec 2028 | 10 |
| NCT05908084Kidney Failure, Chronic · United States | 3 | Active, not recruiting | Jun 2027 | 121 |
| NCT03005418Wounds and Injuries · United States, Israel | 3 | Completed | Sep 19, 2023 | 72 |
How it is read
Names in the registry
- “Acellular Tissue Engineered Vessel (ATEV)”, 2 entries
- “Acellular Tissue Engineered Vessel”, 1 entry
- “Acellular Tissue Engineered Vessel (Symvess)”, 1 entry
Conditions, from the studies’ own filings
- Vascular System Injuries, 2 studies
- Wounds and Injuries, 1 study
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.